Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate. 103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2001-02, Vol.357 (9253), p.336-341 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 341 |
|---|---|
| container_issue | 9253 |
| container_start_page | 336 |
| container_title | The Lancet (British edition) |
| container_volume | 357 |
| creator | Tu, Shi-Ming Millikan, Randall E Mengistu, Bayabel Delpassand, Ebrahim S Amato, Robert J Pagliaro, Lance C Daliani, Danai Papandreou, Christos N Smith, Terry L Kim, Jeri Podoloff, Donald A Logothetis, Christopher J |
| description | Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.
103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating withestramustine and vinblastine. After two or three cycles ofinduction chemotherapy, we randomly assigned 72patients who were clinically stable or responders to receivedoxorubicin with or without strontium-89 (Sr-89) every week for 6 weeks.
Overall 62 of the 103 (60%, 95% CI 50–70)patients had a 50% or greater reduction in serum prostatespecificantigen concentration that was maintained for at least 8 weeks, and 43 (42%, 32–52) had an 80% or greaterreduction. 49 (52%) patients with bone pain at registrationhad complete resolution of pain. After follow-up of 67patients until death, the estimated median survival for all103 patients was 17·5 months (range 0·5–37·7). For the36 patients randomly assigned to receive Sr-89 anddoxorubicin, the median survival time was 27·7 months(4·9–37·7), and for the 36 who received doxorubicin aloneit was 16·8 months (4·4–34·2) (p=0·0014). The hazardratio was 2·76 (95% CI 1·44–5·29).
Bone-targeted consolidation therapyconsisting of one dose of Sr-89 plus doxorubicin once aweek for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival. |
| doi_str_mv | 10.1016/S0140-6736(00)03639-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70588359</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673600036394</els_id><sourcerecordid>68588419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-9da43efa5452940d54979c22975eeb8dad149312e775972f1c5ba08b083229d13</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModlv9CErwQerD6M0kmUx8ES3-WSj4oIJvIZvcaVN2kzHJFvrtzXQXBV98SSD8zs255xDyjMFrBmx48w2YgG5QfDgHeAV84LoTD8iKCSU6KdTPh2T1Bzkhp6XcAIAYQD4mJ4z1DLQWKxI_pIhdtfkKK3parzHb-Y5OKVPrb2107dFGn9MVxi5EjzO2I1bqbHYhpp2laVpkdM6pVFvxLbU0N0nahdLE87UtSNdrWnOw2yfk0WS3BZ8e7zPy49PH7xdfusuvn9cX7y87x8exdtpbwXGyUsheC_BSaKVd32slETejt54JzVmPSkmt-ok5ubEwbmDkDfKMn5GXh7nN1a89lmqaG4fbrY2Y9sUokOPIpW7gi3_Am7TPsXkzTGsQPQfRIHmAXNuxZJzMnMPO5jvDwCxtmPs2zBK1ATD3bZhF9_w4fL_Zof-rOsbfgHcHAFsWtwGzKS7gEnrI6KrxKfzni9-e05k0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199042304</pqid></control><display><type>article</type><title>Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Business Source Complete</source><creator>Tu, Shi-Ming ; Millikan, Randall E ; Mengistu, Bayabel ; Delpassand, Ebrahim S ; Amato, Robert J ; Pagliaro, Lance C ; Daliani, Danai ; Papandreou, Christos N ; Smith, Terry L ; Kim, Jeri ; Podoloff, Donald A ; Logothetis, Christopher J</creator><creatorcontrib>Tu, Shi-Ming ; Millikan, Randall E ; Mengistu, Bayabel ; Delpassand, Ebrahim S ; Amato, Robert J ; Pagliaro, Lance C ; Daliani, Danai ; Papandreou, Christos N ; Smith, Terry L ; Kim, Jeri ; Podoloff, Donald A ; Logothetis, Christopher J</creatorcontrib><description>Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.
103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating withestramustine and vinblastine. After two or three cycles ofinduction chemotherapy, we randomly assigned 72patients who were clinically stable or responders to receivedoxorubicin with or without strontium-89 (Sr-89) every week for 6 weeks.
Overall 62 of the 103 (60%, 95% CI 50–70)patients had a 50% or greater reduction in serum prostatespecificantigen concentration that was maintained for at least 8 weeks, and 43 (42%, 32–52) had an 80% or greaterreduction. 49 (52%) patients with bone pain at registrationhad complete resolution of pain. After follow-up of 67patients until death, the estimated median survival for all103 patients was 17·5 months (range 0·5–37·7). For the36 patients randomly assigned to receive Sr-89 anddoxorubicin, the median survival time was 27·7 months(4·9–37·7), and for the 36 who received doxorubicin aloneit was 16·8 months (4·4–34·2) (p=0·0014). The hazardratio was 2·76 (95% CI 1·44–5·29).
Bone-targeted consolidation therapyconsisting of one dose of Sr-89 plus doxorubicin once aweek for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(00)03639-4</identifier><identifier>PMID: 11210994</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Androgens ; Antineoplastic Agents - administration & dosage ; Bone Neoplasms - mortality ; Bone Neoplasms - prevention & control ; Bone Neoplasms - secondary ; Bones ; Carcinoma - drug therapy ; Carcinoma - mortality ; Chemotherapy ; Clinical trials ; Doxorubicin - administration & dosage ; Hormones ; Humans ; Irradiation ; Male ; Middle Aged ; Pain ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Strontium ; Strontium Radioisotopes - therapeutic use ; Survival Analysis ; Texas - epidemiology ; Therapy</subject><ispartof>The Lancet (British edition), 2001-02, Vol.357 (9253), p.336-341</ispartof><rights>2001 Elsevier Ltd</rights><rights>Copyright Lancet Ltd. Feb 3, 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c388t-9da43efa5452940d54979c22975eeb8dad149312e775972f1c5ba08b083229d13</citedby><cites>FETCH-LOGICAL-c388t-9da43efa5452940d54979c22975eeb8dad149312e775972f1c5ba08b083229d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673600036394$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11210994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tu, Shi-Ming</creatorcontrib><creatorcontrib>Millikan, Randall E</creatorcontrib><creatorcontrib>Mengistu, Bayabel</creatorcontrib><creatorcontrib>Delpassand, Ebrahim S</creatorcontrib><creatorcontrib>Amato, Robert J</creatorcontrib><creatorcontrib>Pagliaro, Lance C</creatorcontrib><creatorcontrib>Daliani, Danai</creatorcontrib><creatorcontrib>Papandreou, Christos N</creatorcontrib><creatorcontrib>Smith, Terry L</creatorcontrib><creatorcontrib>Kim, Jeri</creatorcontrib><creatorcontrib>Podoloff, Donald A</creatorcontrib><creatorcontrib>Logothetis, Christopher J</creatorcontrib><title>Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.
103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating withestramustine and vinblastine. After two or three cycles ofinduction chemotherapy, we randomly assigned 72patients who were clinically stable or responders to receivedoxorubicin with or without strontium-89 (Sr-89) every week for 6 weeks.
Overall 62 of the 103 (60%, 95% CI 50–70)patients had a 50% or greater reduction in serum prostatespecificantigen concentration that was maintained for at least 8 weeks, and 43 (42%, 32–52) had an 80% or greaterreduction. 49 (52%) patients with bone pain at registrationhad complete resolution of pain. After follow-up of 67patients until death, the estimated median survival for all103 patients was 17·5 months (range 0·5–37·7). For the36 patients randomly assigned to receive Sr-89 anddoxorubicin, the median survival time was 27·7 months(4·9–37·7), and for the 36 who received doxorubicin aloneit was 16·8 months (4·4–34·2) (p=0·0014). The hazardratio was 2·76 (95% CI 1·44–5·29).
Bone-targeted consolidation therapyconsisting of one dose of Sr-89 plus doxorubicin once aweek for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Androgens</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - prevention & control</subject><subject>Bone Neoplasms - secondary</subject><subject>Bones</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - mortality</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Doxorubicin - administration & dosage</subject><subject>Hormones</subject><subject>Humans</subject><subject>Irradiation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pain</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Strontium</subject><subject>Strontium Radioisotopes - therapeutic use</subject><subject>Survival Analysis</subject><subject>Texas - epidemiology</subject><subject>Therapy</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkV9rFDEUxYModlv9CErwQerD6M0kmUx8ES3-WSj4oIJvIZvcaVN2kzHJFvrtzXQXBV98SSD8zs255xDyjMFrBmx48w2YgG5QfDgHeAV84LoTD8iKCSU6KdTPh2T1Bzkhp6XcAIAYQD4mJ4z1DLQWKxI_pIhdtfkKK3parzHb-Y5OKVPrb2107dFGn9MVxi5EjzO2I1bqbHYhpp2laVpkdM6pVFvxLbU0N0nahdLE87UtSNdrWnOw2yfk0WS3BZ8e7zPy49PH7xdfusuvn9cX7y87x8exdtpbwXGyUsheC_BSaKVd32slETejt54JzVmPSkmt-ok5ubEwbmDkDfKMn5GXh7nN1a89lmqaG4fbrY2Y9sUokOPIpW7gi3_Am7TPsXkzTGsQPQfRIHmAXNuxZJzMnMPO5jvDwCxtmPs2zBK1ATD3bZhF9_w4fL_Zof-rOsbfgHcHAFsWtwGzKS7gEnrI6KrxKfzni9-e05k0</recordid><startdate>20010203</startdate><enddate>20010203</enddate><creator>Tu, Shi-Ming</creator><creator>Millikan, Randall E</creator><creator>Mengistu, Bayabel</creator><creator>Delpassand, Ebrahim S</creator><creator>Amato, Robert J</creator><creator>Pagliaro, Lance C</creator><creator>Daliani, Danai</creator><creator>Papandreou, Christos N</creator><creator>Smith, Terry L</creator><creator>Kim, Jeri</creator><creator>Podoloff, Donald A</creator><creator>Logothetis, Christopher J</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20010203</creationdate><title>Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial</title><author>Tu, Shi-Ming ; Millikan, Randall E ; Mengistu, Bayabel ; Delpassand, Ebrahim S ; Amato, Robert J ; Pagliaro, Lance C ; Daliani, Danai ; Papandreou, Christos N ; Smith, Terry L ; Kim, Jeri ; Podoloff, Donald A ; Logothetis, Christopher J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-9da43efa5452940d54979c22975eeb8dad149312e775972f1c5ba08b083229d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Androgens</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - prevention & control</topic><topic>Bone Neoplasms - secondary</topic><topic>Bones</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - mortality</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Doxorubicin - administration & dosage</topic><topic>Hormones</topic><topic>Humans</topic><topic>Irradiation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pain</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Strontium</topic><topic>Strontium Radioisotopes - therapeutic use</topic><topic>Survival Analysis</topic><topic>Texas - epidemiology</topic><topic>Therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tu, Shi-Ming</creatorcontrib><creatorcontrib>Millikan, Randall E</creatorcontrib><creatorcontrib>Mengistu, Bayabel</creatorcontrib><creatorcontrib>Delpassand, Ebrahim S</creatorcontrib><creatorcontrib>Amato, Robert J</creatorcontrib><creatorcontrib>Pagliaro, Lance C</creatorcontrib><creatorcontrib>Daliani, Danai</creatorcontrib><creatorcontrib>Papandreou, Christos N</creatorcontrib><creatorcontrib>Smith, Terry L</creatorcontrib><creatorcontrib>Kim, Jeri</creatorcontrib><creatorcontrib>Podoloff, Donald A</creatorcontrib><creatorcontrib>Logothetis, Christopher J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tu, Shi-Ming</au><au>Millikan, Randall E</au><au>Mengistu, Bayabel</au><au>Delpassand, Ebrahim S</au><au>Amato, Robert J</au><au>Pagliaro, Lance C</au><au>Daliani, Danai</au><au>Papandreou, Christos N</au><au>Smith, Terry L</au><au>Kim, Jeri</au><au>Podoloff, Donald A</au><au>Logothetis, Christopher J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2001-02-03</date><risdate>2001</risdate><volume>357</volume><issue>9253</issue><spage>336</spage><epage>341</epage><pages>336-341</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Prostate carcinoma is linked to osteoblasticmetastasis. We therefore investigated the value of bonetargetedconsolidation therapy in selected patients with advanced androgen-independent carcinoma of the prostate.
103 patients received induction chemotherapy, consisting of ketoconazole and doxorubicin alternating withestramustine and vinblastine. After two or three cycles ofinduction chemotherapy, we randomly assigned 72patients who were clinically stable or responders to receivedoxorubicin with or without strontium-89 (Sr-89) every week for 6 weeks.
Overall 62 of the 103 (60%, 95% CI 50–70)patients had a 50% or greater reduction in serum prostatespecificantigen concentration that was maintained for at least 8 weeks, and 43 (42%, 32–52) had an 80% or greaterreduction. 49 (52%) patients with bone pain at registrationhad complete resolution of pain. After follow-up of 67patients until death, the estimated median survival for all103 patients was 17·5 months (range 0·5–37·7). For the36 patients randomly assigned to receive Sr-89 anddoxorubicin, the median survival time was 27·7 months(4·9–37·7), and for the 36 who received doxorubicin aloneit was 16·8 months (4·4–34·2) (p=0·0014). The hazardratio was 2·76 (95% CI 1·44–5·29).
Bone-targeted consolidation therapyconsisting of one dose of Sr-89 plus doxorubicin once aweek for 6 weeks, when given to patients with stable or responding advanced androgen-independent carcinoma of the prostate after induction chemotherapy, improved overall survival.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>11210994</pmid><doi>10.1016/S0140-6736(00)03639-4</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2001-02, Vol.357 (9253), p.336-341 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70588359 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Business Source Complete |
| subjects | Adult Aged Aged, 80 and over Androgens Antineoplastic Agents - administration & dosage Bone Neoplasms - mortality Bone Neoplasms - prevention & control Bone Neoplasms - secondary Bones Carcinoma - drug therapy Carcinoma - mortality Chemotherapy Clinical trials Doxorubicin - administration & dosage Hormones Humans Irradiation Male Middle Aged Pain Prostate cancer Prostate-Specific Antigen - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Strontium Strontium Radioisotopes - therapeutic use Survival Analysis Texas - epidemiology Therapy |
| title | Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A00%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone-targeted%20therapy%20for%20advanced%20androgen-independent%20carcinoma%20of%20the%20prostate:%20a%20randomised%20phase%20II%20trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Tu,%20Shi-Ming&rft.date=2001-02-03&rft.volume=357&rft.issue=9253&rft.spage=336&rft.epage=341&rft.pages=336-341&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(00)03639-4&rft_dat=%3Cproquest_cross%3E68588419%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199042304&rft_id=info:pmid/11210994&rft_els_id=S0140673600036394&rfr_iscdi=true |